After strong FY20, Alembic Pharma's FY21 outlook, too, remains firm

Domestic growth rebounds to double digits; will keep overall momentum on even keel

Alembic Pharmaceuticals’ (Alembic Pharma’s) strong performance, led by its US and India businesses, saw the stock gain over 8 per cent on Friday, and another 7.7 per cent on Monday. While the results showed no impact of coronavirus disease (Covid-19)-led disruptions (either on supplies or raw material), the company has sustained double-digit growth trajectory in the March quarter (Q4) after witnessing volatility in the past.

The revival in domestic market growth has helped steady the ship for Alembic Pharma, which has continued to see regular traction in the US. The branded India sales (28 per cent of overall) grew 13